Clal Biotechnology Industries Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Avi Fischer

Geschäftsführender

₪586.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7yrs

Jüngste Management Updates

Recent updates

Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt

Oct 09

The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet

Apr 18

Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)

Jul 14

Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?

Jan 19

Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings

Mar 25

Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly

Mar 24

Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year

Feb 16

What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?

Jan 12

Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?

Dec 07

Geschäftsführer

Avi Fischer (68 yo)

less than a year

Amtszeit

₪586,000

Vergütung

Dr. Avraham Matityahu Fischer, also known as Avi, M.D., is Co-Managing Partner of Fischer Behar Chen Well Orion & Co. Dr. Fischer is Deputy CEO, Executive VP and Deputy Chairman of Idb Development Corporat...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Avraham Fischer	Chairman & CEO	less than a year	₪586.00k	keine Daten
Liat Nissan	Chief Financial Officer	2.1yrs	₪975.00k	keine Daten
Iris Sadeh	Accountant	2.8yrs	keine Daten	keine Daten
Shiran Manor	General Counsel & Corporate Secretary	no data	keine Daten	keine Daten
Etty Kliger	Vice President of Research & Development - MediWound	no data	₪1.10m	keine Daten
Lior Rosenberg	Vice President of Medical Technologies - MediWound	no data	₪1.21m	keine Daten
Arnon Aharon	Medical Director	2.8yrs	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

61.5yo

Durchschnittliches Alter

Erfahrenes Management: CBIDas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Avraham Fischer	Chairman & CEO	21.5yrs	₪586.00k	keine Daten
Yuval Yanai	External Independent Director	8.9yrs	keine Daten	keine Daten
Gonen Bieber	Director	less than a year	keine Daten	keine Daten
Gad Keren	Independent External Director	4.8yrs	keine Daten	keine Daten
Gabriel Barabash	Director	21.7yrs	keine Daten	keine Daten
Nufar Malovani	Director	7yrs	keine Daten	keine Daten
Tomer Babai	Director	6.9yrs	keine Daten	keine Daten

7.0yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: CBIDie Vorstandsmitglieder gelten als erfahren (7 Jahre durchschnittliche Amtszeit).

Clal Biotechnology Industries Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt

New major risk - Financial position

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Share price stability

The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet

Third quarter 2022 earnings released: ₪0.015 loss per share (vs ₪0.12 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: ₪0.22 loss per share (vs ₪0.22 loss in 2Q 2021)

Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings

Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS ₪0.68 (vs ₪0.96 loss in FY 2019)

ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

New 90-day low: ₪1.75

Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year

New 90-day high: ₪2.24

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day high: ₪2.23

What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?

Novartis AG (SWX:NOVN) reached a definitive agreement to acquire Cadent Therapeutics, Inc. from a group of sellers for approximately $770 million.

ChemomAb Ltd. entered into a definitive merger agreement to acquire Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?

New 90-day low: ₪1.58

New 90-day high: ₪1.87

New 90-day high - ₪1.76

BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Neon Therapeutics, Inc. (NasdaqGS:NTGN) from Third Rock Ventures, LLC and others.

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter